Posted on 05/25/2022 12:57:52 PM PDT by ConservativeMind
Biomedical informatics researchers have found that patients hospitalized with COVID-19 pneumonia had a 13.5% survival advantage when treated with a combination of leukotriene inhibitors (LTIs) and the steroid dexamethasone.
The study shows that patients with low oxygen saturations who are treated with leukotriene inhibitors in addition to dexamethasone have a 13.5% inpatient survival advantage in COVID 19 infection. Patients on LTIs prior to hospitalization who were continued on their LTI had a 22% survival advantage.
…"This represents a new treatment with very strong results and when implemented, should save lives broadly," said Elkin.
The 13.5% survival advantage was found in severely ill patients presenting with oxygen saturation of 50% or less.
The researchers also found that treating severely ill COVID-19 patients with dexamethasone alone did not have any beneficial effect on mortality or morbidity.
"I knew that IL6 and IL8 (interleukin 6 and 8) were bad prognostic indicators in ARDS," said Elkin. "I also knew leukotriene inhibitors decrease these inflammatory mediators, so we hypothesized that they may be useful in decreasing mortality and morbidity in COVID-19 pneumonia."
Patients treated with LTIs had lower rates of inflammation and the "cytokine storm" seen in COVID-19 pneumonia.
Patients in the study who had asthma, and who were found to be at higher risk for severe outcomes from COVID-19 did better when treated with LTIs and dexamethasone than did patients with asthma who weren't treated with these drugs.
Elkin noted that patients who were being treated with the combination of LTIs and dexamethasone were in general more compromised than patients who weren't treated with this combination.
"This makes it likely that our finding of 13.5% improved survival is an underestimate of the true effect, as the LTI users were in general had more comorbidities than the patients who weren't treated with LTIs," he said.
(Excerpt) Read more at medicalxpress.com ...
So does that mean it will either be banned or the government will buy all of it and make it unavailable?
“Some natural compounds may block either the production of leukotrienes or their binding to their receptors. These include active compounds from plants such as aloe, butterbur, black cumin, and boswellia, as well as the well known antioxidant resveratrol.
“The most widely used leukotriene receptor blockers are those preventing cysteinyl leukotrienes from binding to their receptor CysLT1. The main commercial drugs in this category are montelukast, zafirlukast, and pranlukast.
For these severe Covid patients, get them breathing from an oxygen concentrator. These cheap machines put out about 99% oxygen. Extracting oxygen from the air..
I have sa personal reason to ask if anyone has any data on treating “Covid19 pneumonia” with Remdesivir ?
It that the purple inhaler?
This goes against the position that the vaccine is a cure and therefore it must be blocked.
There’s a reasonable amount on it, but it is of limited help.
Collected research:
Imagine that.
Singulair works.
Advair works
This could be why most asthma patients have not had really bad COVID. We thought that we would be dropping like flies but a good number of us take Singulair daily. Also, that steroid is a go-to for me when it turns into Bronchitis.
2 years too late.
PFL
50% oxygen sat? Those folks were knocking on heaven’s door.
Thanks for the info. I wonder what it would take to get a doc to try this.
Give them this study writeup or the direct link to the study, at the bottom of the writeup.
What about JAK inhibitors for the cytokine storm?
Yes
You know I heard this way in the beginning of covid then it disappeared off the radar.
Murdering medics
It would too, since it’s a steroid. Singulair works by a different mechanism.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.